Japan Conjugate Vaccine Market by Disease Indication and End-User - Forecast to 2023 - ResearchAndMarkets.com
(WorldNews Japan)

DUBLIN--(BUSINESS WIRE)--Aug 16, 2018--The `Japan Conjugate Vaccine Market (2018-2023)` report has been added to ResearchAndMarkets.com`s offering. Japan is one of the most prominent markets of conjugate vaccines. Japan, at 84 years, has one of the highest life expectancies in the world. Currently, both PPSV-23 and PCV-13 are available for the elderly for the prevention of Streptococcus pneumoniae-related diseases. Despite these two vaccines being made available for the elderly, the national...